Table 2.
Therapeutic effects, adverse events and regimen changes in the four patient groups
| Total | Non-CKD | CKD group | Subtotal of CKD groups | P value* | |||
|---|---|---|---|---|---|---|---|
| Mild CKD | Moderate CKD | Severe CKD | |||||
| n = 241 | n = 87 | n = 93 | n = 43 | n = 18 | n = 154 | ||
| Therapeutic effects | |||||||
| In-hospital TB-related death | 14 (5.8%) | 3 (3.4%) | 5 (5.4%) | 5 (11.6%) | 1 (5.6%) | 11 (7.1%) | 0.310 |
| Sputum culture conversion at 2 months† | 174 (78.0%) | 67 (77.9%) | 66 (76.7%) | 28 (77.8%) | 13 (86.7%) | 107 (78.1%) | 0.864 |
| Any adverse events | 60 (24.9%) | 18 (20.7%) | 19 (20.4%) | 15 (34.9%) | 8 (44.4%) | 42 (27.3%) | 0.051 |
| No adverse event | 181 (75.1%) | 69 (79.3%) | 74 (79.6%) | 28 (65.1%) | 10 (55.6%) | 112 (72.7%) | – |
| Drug-induced hepatitis | 28 (11.6%) | 6 (6.9%) | 12 (12.9%) | 8 (18.6%) | 2 (11.1%) | 22 (14.3%) | 0.252 |
| Cutaneous reaction | 19 (7.9%) | 8 (9.2%) | 6 (6.5%) | 3 (7.0%) | 2 (11.1%) | 11 (7.1%) | 0.855 |
| Drug-induced nephropathy | 7 (2.9%) | 0 (0%) | 0 (0%) | 5 (11.6%) | 2 (11.1%) | 7 (4.5%) | N/A‡ |
| Gastrointestinal disorder | 6 (2.5%) | 1 (1.1%) | 2 (2.2%) | 1 (2.3%) | 2 (11.1%) | 5 (3.2%) | N/A |
| Gout attack | 5 (2.1%) | 4 (4.6%) | 0 (0%) | 0 (0%) | 1 (5.6%) | 1 (0.6%) | N/A |
| Haematotoxicity | 3 (1.2%) | 0 (0%) | 2 (2.2%) | 0 (0%) | 1 (5.6%) | 3 (1.9%) | N/A |
| Peripheral neuropathy | 1 (0.4%) | 1 (1.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | N/A |
| Anaphylaxis | 1 (0.4%) | 0 (0%) | 0 (0%) | 1 (2.3%) | 0 (0%) | 1 (0.6%) | N/A |
| Regimen change | 28 (11.6%) | 3 (3.4%) | 10 (10.8%) | 9 (20.9%) | 6 (33.3%) | 25 (16.2%) | < 0.001 |
There was some overlap
*Chi-square test was used to compare for each parameter
‡N/A, chi-square test was not applicable because of insufficient expected values in some cells
§The number of patients alive at 2 months was 223 (86 patients in the non-CKD group, 86 in the mild CKD group, 36 in the moderate CKD group and 15 in the severe CKD group)
CKD chronic kidney disease